A preparing method of drug carrying nanoparticles for targeted treatment of malignant lymphoma

A malignant lymphoma, drug-loaded nanotechnology, applied in the field of preparation of drug-loaded nanoparticles, can solve the problems of short half-life, multi-drug resistance of tumor cells, etc., to reduce damage, improve bioavailability and tumor targeting efficiency effect

Inactive Publication Date: 2019-01-01
SOUTH CHINA UNIV OF TECH
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Doxorubicin is a broad-spectrum antitumor antibiotic drug, which is widely used and has good curative effect on a variety of tumors. However, due to its short half-

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A preparing method of drug carrying nanoparticles for targeted treatment of malignant lymphoma
  • A preparing method of drug carrying nanoparticles for targeted treatment of malignant lymphoma
  • A preparing method of drug carrying nanoparticles for targeted treatment of malignant lymphoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] 1. Weigh 0.2g of PEG-PLGA-COOH and dissolve it in 4-5ml of dichloromethane.

[0036] 2. Weigh 0.02g of doxorubicin hydrochloride and dissolve it in 2ml of DMSO, add 40mg of triethylamine, stir for 4-12 hours, dehydrochloride doxorubicin hydrochloride, then add it to the liquid obtained in step 1, and ultrasonicate for 5 minutes to make Doxorubicin is uniformly dispersed in the liquid.

[0037] 3. Precisely weigh 0.5 g of sodium cholate and dissolve it in 50 ml of deionized water to prepare a 1% sodium cholate solution; prepare a 0.5% sodium cholate solution in the same way.

[0038] 4. Mix the liquid obtained in step 2 into the solution (20mL) prepared in step 1, and use an ultrasonic instrument at 120W to sonicate for 1 minute, so that the drug is evenly dispersed in the organic phase.

[0039] 5. Use a 5ml syringe to draw the solution in step 4, and add it dropwise to the 1% sodium cholate solution under the condition of ultrasound (180W, 5min) of the cell disruptor....

Embodiment 2

[0044] 1. Weigh 0.2g of PEG-PLGA and dissolve it in 4-5ml of dichloromethane.

[0045] 2. Weigh 0.02g of doxorubicin hydrochloride and dissolve it in 2ml of DMSO, add 40mg of triethylamine, stir for 4-12 hours, dehydrochloride doxorubicin hydrochloride, then add it to the liquid obtained in step 1, and ultrasonicate for 5 minutes to make Doxorubicin is uniformly dispersed in the liquid.

[0046] 3. Precisely weigh 0.5 g of sodium cholate and dissolve it in 50 ml of deionized water to prepare a 1% sodium cholate solution; prepare a 0.5% sodium cholate solution in the same way.

[0047] 4. Mix the liquid obtained in step 2 into the solution (20 mL) prepared in step 1, and use an ultrasonic instrument at 80 W for 1 minute to disperse the drug evenly in the organic phase.

[0048] 5. Use a 5ml syringe to draw the solution in step 4, and add it dropwise to the 1% sodium cholate solution under the condition of ultrasound (180W, 5min) of the cell disruptor. It can be observed that the...

Embodiment 3

[0053] 1. Weigh 0.2g of PEG-PLGA and dissolve it in 4-5ml of dichloromethane.

[0054] 2. Weigh 0.02g of doxorubicin hydrochloride and dissolve it in 2ml of DMSO, add 40mg of triethylamine, stir for 4-12 hours, dehydrochloride doxorubicin hydrochloride, then add it to the liquid obtained in step 1, and ultrasonicate for 5 minutes to make Doxorubicin is uniformly dispersed in the liquid.

[0055] 3. Precisely weigh 0.5 g of sodium cholate and dissolve it in 50 ml of deionized water to prepare a 1% sodium cholate solution; prepare a 0.5% sodium cholate solution in the same way.

[0056] 4. Mix the liquid obtained in step 2 into the solution (20mL) prepared in step 1, and use an ultrasonic instrument at 300W to sonicate for 1 minute, so that the drug is evenly dispersed in the organic phase.

[0057] 5. Use a 5ml syringe to draw the solution in step 4, and add it dropwise to the 1% sodium cholate solution under the condition of ultrasound (180W, 5min) of the cell disruptor. It c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A preparing method of drug carrying nanoparticles for targeted treatment of malignant lymphoma is disclosed. An amphoteric polymer PEG-PLGA having good biocompatibility is adopted as a carrier center,a hydrophobic segment covers and carries a hydrophobic drug that is adriamycin (DOX), and carboxyl exposed at the outer end is activated through a chemical reaction and is boned with a nucleic acid aptamer having amino. The drug carrying nanoparticles are rapidly delivered to a tumor position by utilizing the targeting function of the nucleic acid aptamer, and the drug is released slowly by utilizing the sustained release function of the PEG-PLGA nanoparticles, thus achieving long-acting efficient treatment of the malignant lymphoma, and reducing side effects caused by common therapies such as chemotherapy.

Description

technical field [0001] The invention belongs to the technical field of biochemical medicine. The invention relates to a preparation method of drug-loaded nanoparticles for targeted treatment of malignant lymphoma. Background technique [0002] Specific nucleic acid aptamer (Aptamer) is a small molecule ligand (usually 20-50 bases) composed of oligopeptide nucleotides, which can specifically bind to the corresponding target. Compared with antibodies, it has the following advantages: 1. Low molecular weight (8-25kDa), penetrates tissues more quickly and reaches the target position; 2. Non-immunogenic, not easily recognized by the immune system; 3. Has thermal stability; 4. It can be synthesized and modified in large quantities; 5. Compared with the preparation cost of antibodies, the preparation cost of nucleic acid aptamers is relatively much lower. [0003] CD30 molecule is a specific marker of malignant lymphoma, which is widely expressed on the surface of Hodgkin's lymph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K47/69A61K47/54A61K31/704A61P35/00
CPCA61K31/704A61K47/549A61K47/6937A61P35/00
Inventor 魏坤罗逍牛雪明万淑倩莫灿龙
Owner SOUTH CHINA UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap